Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

 April 20, 2026

Pharmaphorum

UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

M&A / DealsNeuroscienceRead full story

Post navigation

Magazine: Digital twins become the new battleground for CDMOs →
← UCB to purchase Neurona and NRTX-1001 for $1.15bn

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com